Ryu Hyewon, Baek Seung Woo, Moon Ji Young, Jo In-Sook, Kim Nayoung, Lee Hyo Jin
Department of Internal Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea.
Department of Medical Science, School of Medicine Chungnam National University and Chungnam National University Hospital, Daejeon 35015, Republic of Korea.
Mol Clin Oncol. 2018 Jan;8(1):3-8. doi: 10.3892/mco.2017.1470. Epub 2017 Oct 27.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-associated mortality worldwide. Despite recent advances in molecular and clinical research, patients with gastric cancer at an advanced stage have a dismal prognosis and poor survival rates, and systemic treatment relies predominantly on traditional cytotoxic chemotherapy. To improve patients' quality of life and survival, an improved understanding of the complex molecular mechanisms involved in gastric cancer progression and treatment resistance, and of its clinical application in the development of novel targeted therapies, is urgently required. Chemokines are a group of small chemotactic cytokines that interact with seven-transmembrane G-protein-coupled receptors, and this interaction serves a crucial role in various physiological processes, including organ development and the host immune response, to recruit cells to specific sites in the body. There is also accumulating evidence that chemokines and chemokine receptors (CCRs) contribute to tumor development and progression, as well as metastasis. However, research regarding the functional roles of chemokines and their receptors in cancer is dynamic and context-dependent, and much remains to be elucidated, although various aspects have been explored extensively. In gastric cancer, C-C motif CCRs are involved in the biological behavior of tumor cells, including the processes of growth, invasion and survival, as well as the epithelial-mesenchymal transition. In the present review, attention is given to the clinical relevance of C-C motif CCRs in the development, progression, and metastasis of gastric cancer, particularly CCR7 and CCR5, which have been investigated extensively, as well as their potential therapeutic implications.
胃癌是全球第五大常见癌症,也是癌症相关死亡的第三大主要原因。尽管分子和临床研究最近取得了进展,但晚期胃癌患者的预后仍然很差,生存率较低,全身治疗主要依赖于传统的细胞毒性化疗。为了提高患者的生活质量和生存率,迫切需要更好地了解胃癌进展和治疗耐药中涉及的复杂分子机制,以及其在新型靶向治疗开发中的临床应用。趋化因子是一组与七跨膜G蛋白偶联受体相互作用的小趋化细胞因子,这种相互作用在包括器官发育和宿主免疫反应在内的各种生理过程中起着关键作用,可将细胞募集到体内特定部位。越来越多的证据表明,趋化因子和趋化因子受体(CCR)有助于肿瘤的发生、发展以及转移。然而,尽管已经对趋化因子及其受体在癌症中的各个方面进行了广泛研究,但关于它们在癌症中的功能作用的研究是动态的且依赖于具体情况,仍有许多有待阐明。在胃癌中,C-C基序CCR参与肿瘤细胞的生物学行为,包括生长、侵袭和存活过程以及上皮-间质转化。在本综述中,重点关注C-C基序CCR在胃癌发生、发展和转移中的临床相关性,特别是已被广泛研究的CCR7和CCR5,以及它们潜在的治疗意义。